These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Incidence of venous thrombotic events and events of special interest in a retrospective cohort of commercially insured US patients. Weller SC; Porterfield L; Davis J; Wilkinson GS; Chen L; Baillargeon J BMJ Open; 2022 Feb; 12(2):e054669. PubMed ID: 35140157 [TBL] [Abstract][Full Text] [Related]
23. [Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and subsequent anticoagulant therapy for accompanying deep venous thrombosis of the lower limbs]. Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Takaya T; Yamashita T; Hirata K; Koriyama K; Nagamatsu Y; Matsui T; Katayama Y Rinsho Ketsueki; 2014 Jun; 55(6):697-702. PubMed ID: 24975340 [TBL] [Abstract][Full Text] [Related]
24. Romiplostim: a review of its use in immune thrombocytopenia. Keating GM Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355 [TBL] [Abstract][Full Text] [Related]
25. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study. Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441 [TBL] [Abstract][Full Text] [Related]
26. Primary and secondary immune thrombocytopenia (ITP): Time for a rethink. González-López TJ; Provan D; Bárez A; Bernardo-Gutiérrez A; Bernat S; Martínez-Carballeira D; Jarque-Ramos I; Soto I; Jiménez-Bárcenas R; Fernández-Fuertes F Blood Rev; 2023 Sep; 61():101112. PubMed ID: 37414719 [TBL] [Abstract][Full Text] [Related]
27. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. Al-Samkari H; Van Cott EM; Kuter DJ Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804 [TBL] [Abstract][Full Text] [Related]
28. Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. Ayad N; Grace RF; Al-Samkari H Pediatr Blood Cancer; 2022 Mar; 69(3):e29447. PubMed ID: 34962697 [TBL] [Abstract][Full Text] [Related]
29. Massive intrasplenic arterial thrombosis in a patient with chronic ITP during the development of an Evans syndrome. Diez-Feijóo R; Rodríguez-Sevilla JJ; Colomo L; Papaleo N; Maiques JM; Gimeno E; Andrade-Campos M; Abella E; Merchan BM; Calvo X; Jimenez C; Román-Bravo OD; Salar A; Sanchez-Gonzalez B Thromb Res; 2021 Dec; 208():226-229. PubMed ID: 33714615 [TBL] [Abstract][Full Text] [Related]
30. The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP? Saldanha A; Colella MP; Villaça PR; Thachil J; Orsi FA Thromb Res; 2024 Sep; 241():109109. PubMed ID: 39137700 [TBL] [Abstract][Full Text] [Related]
31. The association between idiopathic thrombocytopenic purpura and cardiovascular disease: a retrospective cohort study. Chandan JS; Thomas T; Lee S; Marshall T; Willis B; Nirantharakumar K; Gill P J Thromb Haemost; 2018 Mar; 16(3):474-480. PubMed ID: 29297977 [TBL] [Abstract][Full Text] [Related]
33. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia. Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771 [TBL] [Abstract][Full Text] [Related]
34. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Yusuf HR; Hooper WC; Grosse SD; Parker CS; Boulet SL; Ortel TL Thromb Res; 2015 Jan; 135(1):50-7. PubMed ID: 25456001 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia. Wang X; Bi H; Liu L; Liu Y; Yin L; Yao J; Yu J; Tao W; Wei Y; Li Y; Yin L; Mu H; Du Y; Zhou Z Platelets; 2023 Dec; 34(1):2271568. PubMed ID: 37941414 [TBL] [Abstract][Full Text] [Related]
36. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of thrombotic events in patients with immune thrombocytopenia. Ito S; Fujiwara SI; Ikeda T; Toda Y; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y Ann Hematol; 2020 Jan; 99(1):49-55. PubMed ID: 31853702 [TBL] [Abstract][Full Text] [Related]
38. Older Adults and Immune Thrombocytopenia: Considerations for the Clinician. Crickx E; Mahévas M; Michel M; Godeau B Clin Interv Aging; 2023; 18():115-130. PubMed ID: 36726813 [TBL] [Abstract][Full Text] [Related]
39. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study. Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835 [TBL] [Abstract][Full Text] [Related]
40. Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review. Cuker A; Lal L; Roy A; Elliott C; Carlyle M; Martin C; Haenig J; Viana R Ann Hematol; 2022 Sep; 101(9):1915-1924. PubMed ID: 35849155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]